Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Foghorn Therapeutics Inc. FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact... see more

Recent & Breaking News (NDAQ:FHTX)

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

GlobeNewswire February 8, 2024

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

GlobeNewswire January 8, 2024

Foghorn Therapeutics Announces CFO Departure

GlobeNewswire January 3, 2024

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

GlobeNewswire December 1, 2023

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

PR Newswire November 21, 2023

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

GlobeNewswire November 2, 2023

Flagship Pioneering Launches Pioneering Intelligence

PR Newswire November 1, 2023

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

GlobeNewswire October 24, 2023

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

GlobeNewswire October 13, 2023

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

GlobeNewswire October 4, 2023

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

PR Newswire September 11, 2023

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 5, 2023

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

GlobeNewswire August 31, 2023

Invaio achieves first registration for citrus greening solution featuring Trecise(TM) technology

PR Newswire August 29, 2023

Foghorn Therapeutics Announces Chief Medical Officer Succession

GlobeNewswire August 8, 2023

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

GlobeNewswire August 4, 2023

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

GlobeNewswire June 28, 2023

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire June 7, 2023

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

GlobeNewswire June 5, 2023